Grufity logo
Grufity logo
GOVX

GOVX - GeoVax Labs, Inc. Stock Price, Fair Value and News

$1.15-0.03 (-2.54%)
Market Closed as of 16 Jun 2026, 04:00 pm ET

53/100

GOVX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

53/100

GOVX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

GOVX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

GOVX Price Action

Last 7 days

-13.4%

Last 30 days

-5.7%

Last 90 days

-30.9%

Trailing 12 Months

-95.5%

GOVX RSI Chart

GOVX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

GOVX Valuation

Market Cap

3.3M

Price/Earnings (Trailing)

-0.16

Price/Sales (Trailing)

1.34

Price/Free Cashflow

-0.17

GOVX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

GOVX Fundamentals

GOVX Revenue

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

GOVX Earnings

Earnings (TTM)

-21.4M

Earnings Growth (Yr)

1.79%

Earnings Growth (Qtr)

-19.09%

GOVX Profitability

Return on Equity

-4.3K%

Return on Assets

-716.5%

Free Cashflow Yield

-572.98%

GOVX Investor Care

Shares Dilution (1Y)

409.15%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2026----
20255.6M6.1M3.4M2.5M
2024-300.7K3.1M4.0M
2022356.6K276.9K246.5K81.5K
20211.2M857.2K472.2K385.5K
20201.5M1.8M1.8M1.8M
20191.1M1.2M1.2M1.2M
20181.0M742.0K843.3K963.2K
2017890.5K952.1K1.0M1.1M
2016---828.9K
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About GeoVax Labs, Inc.

GOVX
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is also developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; GEO-EM01 for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. GeoVax Labs, Inc. has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.
 CEO
 WEBSITEgeovax.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES14

GeoVax Labs, Inc. Frequently Asked Questions

GOVX is the stock ticker symbol of GeoVax Labs, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Jun 15 2026, market cap of GeoVax Labs, Inc. is 3.33 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Mon Jun 15 2026, GOVX's PE ratio (Price to Earnings) is -0.16 and Price to Sales (PS) ratio is 1.34. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. GOVX PE ratio will change depending on the future growth rate expectations of investors.